Read by QxMD icon Read

Preexposure prophylaxis

Joseph Larmarange, Valentine Becquet, Jean-Marie Masumbuko, Marcellin Nouaman, Mélanie Plazy, Christine Danel, Serge Eholié
No abstract text is available yet for this article.
March 27, 2018: AIDS
Charlene A Flash, Oluwatobi O Adegboyega, Xiaoying Yu, Carmen Avalos, Syundai Johnson, Kenneth H Mayer, Thomas P Giordano
BACKGROUND: Publicly funded HIV-testing sites can identify HIV preexposure prophylaxis (PrEP) candidates and provide PrEP linkage. SETTING: Harris Health System's HIV clinic, HIV-testing program, and HIV-prevention program (HPP) in Houston, TX, a high HIV-incidence city. METHODS: A prospective assessment of individuals aged 18 years and older recruited from walk-in HIV testing from December 2013 to April 2015 included risk assessment, HIV testing, and self-administered survey, with follow-up surveys at 6 and 12 months and medical record review...
April 1, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
Nicholas Ojile, Donna Sweet, K James Kallail
Introduction: Attitudes of individuals who provide HIV care towards prescribing Preexposure Prophylaxis (PrEP) to at-risk populations have been studied, but few studies indicate if family physicians would be willing to prescribe PrEP as most family physicians do not specialize in HIV medicine. Few data exist on the perceived barriers preventing family physicians from prescribing PrEP. The purpose of this project was to assess the attitudes and perceived barriers of family physicians in Kansas towards prescribing PrEP to high risk patient populations...
May 2017: Kansas Journal of Medicine
Faith E Fletcher, Celia Fisher, Meredith K Buchberg, Brenikki Floyd, Anna Hotton, Angelica Ehioba, Geri Donenberg
Despite the demonstrated effectiveness of preexposure prophylaxis (PrEP) to reduce incident HIV infections, PrEP's potential as an HIV prevention strategy for adolescent populations is unknown. This study assessed perceptions of adolescent PrEP use and clinical trial participation among African American women and their adolescent daughters. We conducted focus group discussions with 15 African American mother/daughter pairs ( N = 30). Findings suggest a general lack of PrEP awareness, favorable attitudes toward adolescent PrEP use, altruistic attitudes regarding research participation among daughters, and less favorable attitudes toward adolescent clinical trial participation among mothers...
February 1, 2018: Journal of Empirical Research on Human Research Ethics: JERHRE
Lisa Hamzah, Elizabeth Hamlyn
PURPOSE OF REVIEW: This review aims to summarize data in the last 18 months on the sexual and reproductive health of perinatally and horizontally infected adolescents and young people living with HIV (age 13-25 years) and to highlight some key issues faced by this group of adolescents as they reach puberty and sexual debut. RECENT FINDINGS: Adolescents and young people living with HIV are a growing cohort worldwide and a significant proportion engage in high-risk sexual activity, pose risk of onward HIV transmission, yet have poor access to sexual and reproductive health (SRH) services and lack the knowledge and support to advocate for their needs...
February 15, 2018: Current Opinion in HIV and AIDS
Angel B Algarin, Gladys E Ibañez
No abstract text is available yet for this article.
February 12, 2018: JAMA Pediatrics
Sybil G Hosek, Craig M Wilson
No abstract text is available yet for this article.
February 12, 2018: JAMA Pediatrics
M Siguier, J-M Molina
Preexposure prophylaxis of HIV with antiretroviral drugs is a prevention tool available in France since 2016, combined with the prevention methods already used (condoms, post-exposure treatment, rapid treatment of diagnosed HIV infections, etc.). It is targeted at populations at high risk of HIV infection, especially men who have sex with men, for whom traditional prevention methods are insufficient. We collected clinical research data, which resulted in the launch of preexposure prophylaxis in the United States and then elsewhere in the world, safety, tolerability and cost data, as well as ongoing research data (new molecules/methods of administration)...
February 9, 2018: Médecine et Maladies Infectieuses
Kate M Mitchell, Dobromir Dimitrov, James P Hughes, Fan Xia, Deborah Donnell, K Rivet Amico, Kevin Bokoch, Anupong Chitwarakorn, Linda-Gail Bekker, Timothy H Holtz, Sharon Mannheimer, Robert M Grant, Marie-Claude Boily
OBJECTIVES: To review the main factors influencing the costs of nondaily oral preexposure prophylaxis (PrEP) with tenofovir (±emtricitabine). To estimate the cost reductions possible with nondaily PrEP compared with daily PrEP for different populations (MSM and heterosexual populations). DESIGN: Systematic review and data triangulation. METHODS: We estimated the required number of tablets/person/week for dosing regimens used in the HPTN 067/ADAPT (daily/time-driven/event-driven) and IPERGAY (on-demand) trials for different patterns of sexual intercourse...
February 8, 2018: AIDS
Robert M Grant, Sharon Mannheimer, James P Hughes, Yael Hirsch-Moverman, Avelino Loquere, Anupong Chitwarakorn, Marcel E Curlin, Maoji Li, K Rivet Amico, Craig W Hendrix, Peter L Anderson, Bonnie J Dye, Mark A Marzinke, Estelle Piwowar-Manning, Laura McKinstry, Vanessa Elharrar, Michael Stirratt, James F Rooney, Susan H Eshleman, Janet M McNicholl, Frits van Griensven, Timothy H Holtz
Background: Nondaily dosing of oral preexposure prophylaxis (PrEP) may provide equivalent coverage of sex events compared with daily dosing. Methods: At-risk men and transgender women who have sex with men were randomly assigned to 1 of 3 dosing regimens: 1 tablet daily, 1 tablet twice weekly with a postsex dose (time-driven), or 1 tablet before and after sex (event-driven), and were followed for coverage of sex events with pre- and postsex dosing measured by weekly self-report, drug concentrations, and electronic drug monitoring...
February 6, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Moira C McNulty, John A Schneider
: The current review re-conceptualizes seek and test strategies, particularly given the changing importance of HIV testing as care continuum entry for persons irrespective of their HIV status. Care continuum entry advances previous seek and test strategies for client engagement with two next-generation functions: use of testing to engage (or re-engage) HIV negative clients in preexposure prophylaxis (PrEP) care; and testing individuals who may already be known positives for care continuum re-entry. We review existing seek and test strategies for most impacted community members with a goal of optimizing care continuum entry as we move towards HIV transmission elimination...
February 20, 2018: AIDS
Samuel M Jenness, Kevin M Weiss, Steven M Goodreau, Thomas Gift, Harrell Chesson, Karen W Hoover, Dawn K Smith, Albert Y Liu, Patrick S Sullivan, Eli S Rosenberg
No abstract text is available yet for this article.
January 23, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Thiago Silva Torres, Raquel Brandini De Boni, Mauricio Tl de Vasconcellos, Paula Mendes Luz, Brenda Hoagland, Ronaldo Ismerio Moreira, Valdilea Gonçalves Veloso, Beatriz Grinsztejn
BACKGROUND: Geosocial networking (GSN) smartphone apps are becoming the main venue for sexual encounters among Brazilian men who have sex with men (MSM). To address the increased HIV incidence in this population, preexposure prophylaxis (PrEP) was recently implemented in the Brazilian public health system in the context of combined HIV prevention. OBJECTIVE: This study aimed to describe the characteristics of MSM using GSN apps for sexual encounters, their awareness of prevention strategies, and willingness to use PrEP...
January 22, 2018: JMIR Public Health and Surveillance
Leah M Adams, Benjamin H Balderson, Kathy Brown, Staci E Bush, Bruce J Packett
Uptake of preexposure prophylaxis (PrEP) has been slow, but is increasing. Although PrEP is indicated for many patients, it has been concentrated among men who have sex with men (MSM). Awareness of PrEP is limited among non-MSM individuals, and among some MSM. As such, individuals at risk for HIV who are unaware of PrEP must rely on their medical providers to initiate conversations about PrEP. Members of a national professional organization of HIV specialists with prescribing privileges, including physicians, nurse practitioners, and physician assistants, participated in an online survey ( n = 342) to characterize their PrEP prescribing behaviors and the demographic membership of their PrEP patients...
January 1, 2018: Health Education & Behavior: the Official Publication of the Society for Public Health Education
Rupa R Patel, Douglas A Luke, Enola K Proctor, William G Powderly, Philip A Chan, Kenneth H Mayer, Laura C Harrison, Amar Dhand
PURPOSE: The aim of this study was to identify sex venue-based networks among men who have sex with men (MSM) to inform HIV preexposure prophylaxis (PrEP) dissemination efforts. METHODS: Using a cross-sectional design, we interviewed MSM about the venues where their recent sexual partners were found. Venues were organized into network matrices grouped by condom use and race. We examined network structure, central venues, and network subgroups. RESULTS: Among 49 participants, the median age was 27 years, 49% were Black and 86% reported condomless anal sex (ncAS)...
January 2018: LGBT Health
Erika Aaron, Cori Blum, Dominika Seidman, Mary Jo Hoyt, Joanne Simone, Meg Sullivan, Dawn K Smith
Preexposure prophylaxis (PrEP) is a highly effective HIV prevention method; however, it is underutilized among women who are at risk for acquisition of HIV. Women comprise one in five HIV diagnoses in the United States, and significant racial disparities in new HIV diagnoses persist. The rate of new HIV diagnoses among black and African American women in 2015 was 16 times greater than that of white women. These disparities highlight the importance of HIV prevention strategies for women, including the use of PrEP...
January 2018: AIDS Patient Care and STDs
Lili Chan, Benjamin Asriel, Ellen F Eaton, Christina M Wyatt
PURPOSE OF REVIEW: The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations. Although TDF is well tolerated, the potential for kidney and bone toxicity has important implications for public health given the large number of individuals exposed to TDF worldwide...
March 2018: Current Opinion in Nephrology and Hypertension
Leah Turner, Abbey Roepke, Emily Wardell, Anne M Teitelman
Oral preexposure prophylaxis (PrEP) has been proven to be a safe and effective means of preventing HIV. The purpose of our literature review was to examine primary care provider knowledge and attitudes about prescribing PrEP. PubMed, CINAHL, Web of Science, and Scopus were searched and additional articles were identified through other sources, yielding 11 articles that met inclusion criteria. Overall, there was high variability among providers regarding attitudes, knowledge, and prescriptive practices related to PrEP...
January 2018: Journal of the Association of Nurses in AIDS Care: JANAC
Isabelle Durand-Zaleski, Pierre Mutuon, Isabelle Charreau, Cecile Tremblay, Daniela Rojas, Gilles Pialoux, Christian Chidiac, Catherine Capitant, Bruno Spire, Laurent Cotte, Julie Chas, Laurence Meyer, Jean Michel Molina
OBJECTIVES: We undertook the economic evaluation of the double-blind randomized ANRS-IPERGAY trial, which showed the efficacy of on-demand preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) in preventing HIV infection among high-risk MSM. DESIGN AND METHODS: The economic evaluation was prospective. Counseling, drugs (TDF-FTC at &OV0556;500.88 for 30 tablets), tests, visits, and hospital admissions were valued based on in-trial use...
January 2, 2018: AIDS
Lucia Taramasso, Niccolò Riccardi, Filippo Del Puente, Bianca Bruzzone, Diego Ripamonti, Beatrice D'Ambrosio, Claudio Viscoli, Antonio Di Biagio
Pre-exposure prophylaxis (PrEP) with TDF/FTC significantly reduces the risk for HIV-1 transmission, but, to date, nobody knows if PrEP can still be useful in case of viruses harboring resistances to TDF/FTC or if alternative antiretroviral drugs might be rather proposed in selected cases. We promote the debate by describing a case of an acute infection with multiresistant HIV that occurred in a young girl who started a relationship with an HIV-infected partner who had a known multiresistant HIV.
January 18, 2018: AIDS Research and Human Retroviruses
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"